Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2018-02-15 Regulatory Filings
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Communiqué en PDF
Regulatory Filings Classification · 97% confidence The document is a press release dated February 15, 2018, announcing a new exclusive distribution agreement between Diaxonhit's subsidiary (eurobio-ingen) and Luminex for the VERIGENE® molecular biology platform in France and the Maghreb. This type of announcement, detailing a strategic business development (a partnership/agreement) rather than routine financial results (ER, IR, 10-K) or mandatory regulatory filings, fits best under a general business update or regulatory announcement category. Since there is no specific category for 'Partnership Announcement' or 'Business Development,' and it is a formal communication intended for the market, it is classified as a general Regulatory Filing (RNS), which serves as a broad category for official company news that doesn't fit elsewhere. The length (6398 chars) is substantial enough that it is not merely a brief 'Report Publication Announcement' (RPA).
2018-02-15 French
Communiqué en PDF
Regulatory Filings Classification · 95% confidence The document is a press release dated January 22, 2017, announcing a significant business development: DIAXONHIT signing an exclusive agreement with RCPAQAP for the marketing of external quality assessment programs in Europe. It details the nature of the agreement, the importance of quality assessment in laboratories, and includes quotes from management. The structure (headline, date, announcement body, management quotes, upcoming financial dates, 'About Us' section, and legal disclaimer) is characteristic of a corporate press release announcing a strategic event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which often serves as a catch-all for significant, non-standardized corporate news releases, or potentially an Earnings Release (ER) if it were announcing results, but here it announces a partnership. Given the content is a strategic partnership announcement, RNS is the most appropriate general classification if a more specific 'Partnership Announcement' code is unavailable. However, looking closely at the definitions, this is a major business update, which often gets classified as RNS (Regulatory Filings) when it's not a standard financial report. It is not an Earnings Release (ER) as it doesn't contain financial results, nor is it a Report Publication Announcement (RPA) as it is the news itself, not an announcement *about* another report.
2018-01-22 French
Communiqué en PDF
M&A Activity Classification · 99% confidence The document is a press release dated September 5, 2017, announcing that DIAXONHIT has completed the acquisition of GENBIO in the US. It details the strategic rationale, the financial terms of the acquisition (US$ 2 million price, payment structure, financing via bank loan), and the expected synergies. This type of announcement, detailing a significant corporate transaction like an acquisition, falls under the category of Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if no other category fits perfectly. Since it explicitly details fundraising/financing aspects (the bank loan used to fund the acquisition payments), 'CAP' is a strong candidate. However, M&A Activity (TAR) is specifically for merger proposals or takeover bids. While this is an acquisition, the focus here is heavily on the financing structure and the strategic integration, which often overlaps with financing updates. Given the options, 'CAP' (Capital/Financing Update) covers the financing details mentioned, but 'TAR' (M&A Activity) is the most precise fit for an acquisition announcement. Since the document is a formal announcement detailing the completion of a merger/acquisition, TAR is the most appropriate classification, even though financing details are included. Reviewing the definitions: TAR is for 'merger proposals or takeover bids'. This is a completed acquisition. CAP is for 'Updates on company fundraising, financing activities, or capital structure changes'. The financing of the acquisition is detailed. Given the primary event is the acquisition itself, TAR is usually preferred for M&A events. If TAR is strictly for *proposals*, then CAP might be safer as it covers financing activities related to the transaction. However, in standard financial classification, the completion of an acquisition is typically classified under M&A/TAR. I will classify it as TAR as the core event is the acquisition.
2017-09-05 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.